OPERA I and II: Identical, head-to-head clinical trials vs Rebif over 2 years 2,4,6

The efficacy and safety of OCREVUS in RMS were studied vs Rebif in 2 double-blind, double-dummy trials evaluating over 1600 patients for 2 years

  • Patients receiving OCREVUS (ocrelizumab) were given a 600 mg IV dose every 24 weeks (dose 1 administered as two 300 mg IV infusions 2 weeks apart) and placebo subcutaneous injections 3 times a week
  • Patients receiving Rebif® (interferon β-1a) were given 44 μg subcutaneous injections 3 times per week and placebo IV infusions every 24 weeks
  • Additional endpoints studied included proportion of patients with confirmed disability improvement and mean number of new T1 hypointense lesions (chronic black holes) per MRI

OCREVUS: OPERA I, n=410; OPERA II, n=417.
Rebif: OPERA I, n=411; OPERA II, n=418.

Three years of data in the OLE period 2

Over 90% of patients who completed the controlled period entered the OLE, and of those, ≈90% completed Year 3 of the OLE

Over 90% of patients who completed the controlled period entered the OLE, and of those, 90% completed Year 3 of the OLE.
  • Patients who received Rebif during the controlled period continued to receive Rebif during the OLE screening period until their first infusion of OCREVUS
  • In the OLE phase, the first 600 mg dose of OCREVUS was administered as two 300 mg infusions given 2 weeks apart
Limitations of OLE data
  • The OLE is an open-label and uncontrolled study period
  • Patients in the OLE period successfully completed the controlled period and are subject to continued dropout; they may represent an enriched population
  • The endpoints measured were not prespecified nor powered to conclude statistical significance; they only convey numerical trends
  • Conclusions regarding the treatment effect of OCREVUS cannot be drawn on the basis of OLE data

The OCREVUS RMS patient 2,6,33

Examine OCREVUS for RMS

Review RMS data in controlled head-to-head trials vs Rebif.

Request information

Speak to an OCREVUS Representative to learn more about OCREVUS.

EDSS=Expanded Disability Status Scale; Gd+=gadolinium-enhancing.